Trending Analyst Recommended Stock: Allergan plc (AGN)

Lloyd Doyle
January 23, 2018

Baupost Group LLC MA now owns 2,964,203 shares of the company's stock worth $607,513,000 after acquiring an additional 531,600 shares during the last quarter. Clark Estates Inc. NY boosted its holdings in Allergan by 120.0% in the 4th quarter. Allergan makes up 5.7% of Intermede Investment Partners Ltd's holdings, making the stock its 4th biggest holding.

A number of other hedge funds also recently added to or reduced their stakes in AGN. The stock traded on impressive volume of 821216 comparing to the average volume of 10941.80 shares, completing picture of exact trends with uncompleted dots in volume over the norm. Commerzbank Aktiengesellschaft FI now owns 67,844 shares of the company's stock worth $16,492,000 after purchasing an additional 11,291 shares during the period. Community Bank & Trust Waco Texas increased its position in Allergan by 0.8% in the 2nd quarter. Company has conspicuous measure of stock oscillations; average true range may be heating up this temperature with value of 0.37.

In other Allergan news, Director Chris W. Bodine acquired 3,030 shares of the business's stock in a transaction that occurred on Thursday, December 7th.

The stock has actually made sharp losses in the past year, as the company has gathered a -15.5% return in the past twelve months. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Allergan by 0.3% in the 2nd quarter. Return on Assets (ROA) value of the stock is -6 Percent. Corporate insiders own 0.36% of the company's stock. Deutsche Bank maintained the shares of AGN in report on Friday, August 7 with "Buy" rating.

Whereas its latest closing price kept its distance from the SMA20 at 6.52% and 11.35% from SMA 50 while it was knocked up 5.60% from the simple moving average price of 200 days. Zacks Investment Research cut shares of Allergan from a "hold" rating to a "sell" rating in a research report on Tuesday, October 17th. Finally, UBS Group reaffirmed a "buy" rating and issued a $275.00 price target on shares of Allergan in a report on Tuesday, September 26th.

Looking at the Analyst Recommendations of the stock, 7 Analysts issued a Buy for MoSys, 7 gave Outperform, 9 analysts gave Hold Rating, 0 issued Underperform and 0 marked the stock as Sell. Price Target plays a critical role when it comes to the analysis of a Stock. Dowling And Yahnke Ltd invested in 0.04% or 2,086 shares. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The stock was purchased at an average cost of $164.74 per share, for a total transaction of $757,804.00. The disclosure for this purchase can be found here. Insiders purchased a total of 17,630 shares of company stock valued at $2,890,057 over the last quarter. Moreover, Frontier Inv Management Company has 0.51% invested in Allergan plc (NYSE:AGN).

At the session level, shares of Allergan plc (NYSE:AGN) moved 3.95% from the open. Short-term as well long term investors always focus on the liquidity of the stocks so for that concern, liquidity measure in recent quarter results of the company was recorded 1.50 as current ratio and on the opponent side the debt to equity ratio was 1.21 and long-term debt to equity ratio also remained 1.13. Allergan plc has a 1 year low of $160.07 and a 1 year high of $256.80. The company has market cap of $62.61 billion. The company reported $4.15 EPS for the quarter, topping the Zacks' consensus estimate of $4.06 by $0.09. During the same period in the prior year, the firm posted $3.32 EPS.

Allergan declared that its Board of Directors has initiated a stock buyback plan on Monday, September 25th that allows the company to buyback $2.00 billion in outstanding shares. The market capitalization of the company is $6 Billion. A value of 25-50 would indicate a strong trend.

COPYRIGHT VIOLATION NOTICE: This story was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another publication, it was illegally copied and reposted in violation of worldwide trademark and copyright law. AGN therefore has an above average level of market risk. The firm offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women??s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer??s disease.

Other reports by Iphone Fresh

Discuss This Article